More Growth Ahead For Farxiga From First-In-Class Kidney Disease Approval
Closing Down Jardiance’s Lead
AstraZeneca’s SGLT2 inhibitor produced 50% growth in Q1, and its new chronic kidney disease approval will give it an edge over Lilly and Boehringer’s Jardiance.
You may also be interested in...
The company, which set a list price of $19 per day, sees awareness of diagnosing chronic kidney disease in type 2 diabetes patients as the top challenge for newly approved finerenone in the US.
Cardiologists in Europe who have so far been unwilling to embrace the SGLT2 class now have two drugs approved for heart failure with reduced ejection fraction, with Jardiance soon to join Farxiga on the market, potentially attractive options especially for their diabetic patients.
Jardiance and Ofev are growing strongly but the German drugmaker is also confident its pipeline will bear fruit, boosted by a rising research budget that represents almost 23% of sales.